Início › Câncer de Pulmão de Não Pequenas Células › Carolina do Sul

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Carolina do Sul

30 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Carolina do Sul.

Cidades em Carolina do Sul

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Saint Joseph's/Candler - Bluffton Campus, Bluffton
Prisma Health Cancer Institute - Spartanburg, Boiling Springs
Bon Secours Saint Francis Hospital, Charleston
e mais 15

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Bon Secours Hematology and Oncology, Greenville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06472245

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #9, Myrtle Beach

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Prisma Health Cancer Institute - Spartanburg, Boiling Springs
Prisma Health Cancer Institute - Easley, Easley
Gibbs Cancer Center-Gaffney, Gaffney
e mais 9

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Saint Joseph's Candler Health System ( Site 4010), Bluffton
Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312137

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Medical University of South Carolina, Florence
Medical University of South Carolina Health Lancaster Medical Center, Lancaster

RecrutandoFase 3

Idades de 18 a 100 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Medical University of South Carolina, Charleston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Medical University of South Carolina, Charleston
Lexington Medical Center, West Columbia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Greenville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06357533

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Medical University of South Carolina /ID# 273272, Charleston
Saint Francis Cancer Center - Greenville /ID# 276368, Greenville

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06568939

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

St Francis Cancer Center, Greenville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

PRISMA Health/ITOR, Greenville

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Greenville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06767514

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Spartanburg Regional, Spartanburg

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Carolina Urologic Research Center, Myrtle Beach

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

MUSC Hollings Cancer Center, Charleston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06750185

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Medical University of South Carolina, Charleston
Prisma Health Cancer Institute, Greenville
Lexington Medical Center, West Columbia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Greenville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07291037

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Medical University of South Carolina, Charleston

RecrutandoFase 3

Idades de 18 a 90 · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT06745908

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson
Saint Joseph's/Candler - Bluffton Campus, Bluffton
Prisma Health Cancer Institute - Spartanburg, Boiling Springs
e mais 9

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 3 de jun. de 2026 · NCT05642572

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA03-0, Charleston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de mai. de 2026 · NCT06953089

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Ralph H Johnson VA Medical Center, Charleston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson

RecrutandoFase 2

18 Minutes · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson
Saint Joseph's/Candler - Bluffton Campus, Bluffton
Medical University of South Carolina, Charleston
e mais 5

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06616584

Phase 2 Study of Fingolimod in Lung Cancers

Hollings Cancer Center at Medical University of South Carolina, Charleston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 30 de mar. de 2026 · NCT06424067

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

AnMed Health Cancer Center, Anderson
Beaufort Memorial Hospital, Beaufort
Saint Joseph's/Candler - Bluffton Campus, Bluffton
e mais 18

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

The Medical University of South Carolina, Charleston

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 5 de fev. de 2026 · NCT05236114

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Investigational Site, Greenville

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jan. de 2026 · NCT06999187

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 123, Charleston
Research Site 108, Greenville

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 21 de nov. de 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Greenville

RecrutandoEstudo observacional

Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.